405 related articles for article (PubMed ID: 12465055)
1. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Fox SH; Henry B; Hill M; Crossman A; Brotchie J
Mov Disord; 2002 Nov; 17(6):1180-7. PubMed ID: 12465055
[TBL] [Abstract][Full Text] [Related]
2. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Johnston TH; Fox SH; McIldowie MJ; Piggott MJ; Brotchie JM
J Pharmacol Exp Ther; 2010 Jun; 333(3):865-73. PubMed ID: 20231306
[TBL] [Abstract][Full Text] [Related]
3. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
[TBL] [Abstract][Full Text] [Related]
4. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD
Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
[TBL] [Abstract][Full Text] [Related]
5. Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia.
Zeng BY; Iravani MM; Jackson MJ; Rose S; Parent A; Jenner P
Neurobiol Dis; 2010 Dec; 40(3):599-607. PubMed ID: 20713157
[TBL] [Abstract][Full Text] [Related]
6. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
7. Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Gomez-Ramirez J; Johnston TH; Visanji NP; Fox SH; Brotchie JM
Mov Disord; 2006 Jun; 21(6):839-46. PubMed ID: 16532454
[TBL] [Abstract][Full Text] [Related]
8. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.
Nash JE; Ravenscroft P; McGuire S; Crossman AR; Menniti FS; Brotchie JM
Exp Neurol; 2004 Aug; 188(2):471-9. PubMed ID: 15246846
[TBL] [Abstract][Full Text] [Related]
9. Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin.
Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
Mov Disord; 2006 Jan; 21(1):9-17. PubMed ID: 16127720
[TBL] [Abstract][Full Text] [Related]
10. Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa.
Kuoppamäki M; Al-Barghouthy G; Jackson M; Smith L; Zeng BY; Quinn N; Jenner P
Mov Disord; 2002 Nov; 17(6):1312-7. PubMed ID: 12465074
[TBL] [Abstract][Full Text] [Related]
11. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
Savola JM; Hill M; Engstrom M; Merivuori H; Wurster S; McGuire SG; Fox SH; Crossman AR; Brotchie JM
Mov Disord; 2003 Aug; 18(8):872-83. PubMed ID: 12889076
[TBL] [Abstract][Full Text] [Related]
12. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
Pearce RK; Banerji T; Jenner P; Marsden CD
Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
[TBL] [Abstract][Full Text] [Related]
13. Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets.
Katzenschlager R; Jackson MJ; Rose S; Stockwell K; Tayarani-Binazir KA; Zubair M; Smith LA; Jenner P; Lees AJ
Mov Disord; 2007 Apr; 22(5):715-9. PubMed ID: 17373723
[TBL] [Abstract][Full Text] [Related]
14. The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.
Koprich JB; Fox SH; Johnston TH; Goodman A; Le Bourdonnec B; Dolle RE; DeHaven RN; DeHaven-Hudkins DL; Little PJ; Brotchie JM
Mov Disord; 2011 Jun; 26(7):1225-33. PubMed ID: 21465551
[TBL] [Abstract][Full Text] [Related]
15. Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate.
Silverdale MA; Nicholson SL; Ravenscroft P; Crossman AR; Millan MJ; Brotchie JM
Exp Neurol; 2004 Jul; 188(1):128-38. PubMed ID: 15191809
[TBL] [Abstract][Full Text] [Related]
16. Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset.
Hill MP; Bezard E; McGuire SG; Crossman AR; Brotchie JM; Michel A; Grimée R; Klitgaard H
Mov Disord; 2003 Nov; 18(11):1301-5. PubMed ID: 14639671
[TBL] [Abstract][Full Text] [Related]
17. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
Hill MP; Ravenscroft P; Bezard E; Crossman AR; Brotchie JM; Michel A; Grimée R; Klitgaard H
J Pharmacol Exp Ther; 2004 Jul; 310(1):386-94. PubMed ID: 15004218
[TBL] [Abstract][Full Text] [Related]
18. Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan.
Fox SH; Henry B; Hill MP; Peggs D; Crossman AR; Brotchie JM
Mov Disord; 2001 Jul; 16(4):642-50. PubMed ID: 11481687
[TBL] [Abstract][Full Text] [Related]
19. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability.
Iravani MM; Tayarani-Binazir K; Chu WB; Jackson MJ; Jenner P
J Pharmacol Exp Ther; 2006 Dec; 319(3):1225-34. PubMed ID: 16959959
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Visanji NP; Gomez-Ramirez J; Johnston TH; Pires D; Voon V; Brotchie JM; Fox SH
Mov Disord; 2006 Nov; 21(11):1879-91. PubMed ID: 16960862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
